The antiarrhythmic and cardiac electrophysiological effects of buprenorphine

G. Boachie-Ansah, R. Sitsapesan, K. A. Kane, J. Parratt

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The effects of buprenorphine, given intravenously, on the incidence and severity of early acute coronary artery occlusion-induced arrhythmias were examined in anaesthetised rats. The electrophysiological effects of buprenorphine were also examined in sheep Purkinje fibres and rat papillary muscles, superfused in vitro with either a normal or a hypoxic, hyperkalaemic and acidotic physiological salt solution (PSS). In anaesthetised rats subjected to acute coronary artery occlusion, pretreatment with buprenorphine (1 mg kg-1 i.v.) markedly reduced the incidence of ventricular extra-systoles during the initial 30 min post-occlusion period. The incidence of ventricular fibrillation (VF) was also significantly reduced from 56% to 10%. At the antiarrhythmic dose (1 mg kg-1), buprenorphine also attenuated the sudden fall in systemic arterial blood pressure induced by acute coronary artery ligation. In normal sheep Purkinje fibres and rat papillary muscles, buprenorphine (10-6-10-5 M) significantly reduced the action potential height and maximum rate of depolarisation of phase zero (MRD) and prolonged the duration of the action potential. Superfusion of sheep Purkinje fibres and rat papillary muscles with a hypoxic, hyperkalaemic and acidotic PSS resulted in marked reductions in resting membrane potential, upstroke and duration of the action potential. In the presence of the modified compared with normal PSS, buprenorphine reduced the action potential height and MRD of both sleep Purkinje fibres and rat papillary muscles to a greater extent, although its ability to prolong the action potential duration was attenuated. The antiarrhythmic effects of buprenorphine observed in vivo may be explained by its direct cardiac electrophysiological effects. Buprenorphine might be useful in relieving pain and in reducing the severity of arrhythmias in the early stages of acute myocardial infarction.

Original languageEnglish
Pages (from-to)801-808
Number of pages8
JournalBritish Journal of Pharmacology
Volume97
Issue number3
Publication statusPublished - 1989

Fingerprint

Buprenorphine
Purkinje Fibers
Papillary Muscles
Action Potentials
Sheep
Coronary Vessels
Salts
Coronary Occlusion
Cardiac Arrhythmias
Incidence
Aptitude
Ventricular Fibrillation
Membrane Potentials
Ligation
Arterial Pressure
Sleep
Myocardial Infarction
Pain

ASJC Scopus subject areas

  • Pharmacology

Cite this

The antiarrhythmic and cardiac electrophysiological effects of buprenorphine. / Boachie-Ansah, G.; Sitsapesan, R.; Kane, K. A.; Parratt, J.

In: British Journal of Pharmacology, Vol. 97, No. 3, 1989, p. 801-808.

Research output: Contribution to journalArticle

Boachie-Ansah, G, Sitsapesan, R, Kane, KA & Parratt, J 1989, 'The antiarrhythmic and cardiac electrophysiological effects of buprenorphine', British Journal of Pharmacology, vol. 97, no. 3, pp. 801-808.
Boachie-Ansah, G. ; Sitsapesan, R. ; Kane, K. A. ; Parratt, J. / The antiarrhythmic and cardiac electrophysiological effects of buprenorphine. In: British Journal of Pharmacology. 1989 ; Vol. 97, No. 3. pp. 801-808.
@article{93f6f8314c854e61a22b6e8ad84c2cf3,
title = "The antiarrhythmic and cardiac electrophysiological effects of buprenorphine",
abstract = "The effects of buprenorphine, given intravenously, on the incidence and severity of early acute coronary artery occlusion-induced arrhythmias were examined in anaesthetised rats. The electrophysiological effects of buprenorphine were also examined in sheep Purkinje fibres and rat papillary muscles, superfused in vitro with either a normal or a hypoxic, hyperkalaemic and acidotic physiological salt solution (PSS). In anaesthetised rats subjected to acute coronary artery occlusion, pretreatment with buprenorphine (1 mg kg-1 i.v.) markedly reduced the incidence of ventricular extra-systoles during the initial 30 min post-occlusion period. The incidence of ventricular fibrillation (VF) was also significantly reduced from 56{\%} to 10{\%}. At the antiarrhythmic dose (1 mg kg-1), buprenorphine also attenuated the sudden fall in systemic arterial blood pressure induced by acute coronary artery ligation. In normal sheep Purkinje fibres and rat papillary muscles, buprenorphine (10-6-10-5 M) significantly reduced the action potential height and maximum rate of depolarisation of phase zero (MRD) and prolonged the duration of the action potential. Superfusion of sheep Purkinje fibres and rat papillary muscles with a hypoxic, hyperkalaemic and acidotic PSS resulted in marked reductions in resting membrane potential, upstroke and duration of the action potential. In the presence of the modified compared with normal PSS, buprenorphine reduced the action potential height and MRD of both sleep Purkinje fibres and rat papillary muscles to a greater extent, although its ability to prolong the action potential duration was attenuated. The antiarrhythmic effects of buprenorphine observed in vivo may be explained by its direct cardiac electrophysiological effects. Buprenorphine might be useful in relieving pain and in reducing the severity of arrhythmias in the early stages of acute myocardial infarction.",
author = "G. Boachie-Ansah and R. Sitsapesan and Kane, {K. A.} and J. Parratt",
year = "1989",
language = "English",
volume = "97",
pages = "801--808",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The antiarrhythmic and cardiac electrophysiological effects of buprenorphine

AU - Boachie-Ansah, G.

AU - Sitsapesan, R.

AU - Kane, K. A.

AU - Parratt, J.

PY - 1989

Y1 - 1989

N2 - The effects of buprenorphine, given intravenously, on the incidence and severity of early acute coronary artery occlusion-induced arrhythmias were examined in anaesthetised rats. The electrophysiological effects of buprenorphine were also examined in sheep Purkinje fibres and rat papillary muscles, superfused in vitro with either a normal or a hypoxic, hyperkalaemic and acidotic physiological salt solution (PSS). In anaesthetised rats subjected to acute coronary artery occlusion, pretreatment with buprenorphine (1 mg kg-1 i.v.) markedly reduced the incidence of ventricular extra-systoles during the initial 30 min post-occlusion period. The incidence of ventricular fibrillation (VF) was also significantly reduced from 56% to 10%. At the antiarrhythmic dose (1 mg kg-1), buprenorphine also attenuated the sudden fall in systemic arterial blood pressure induced by acute coronary artery ligation. In normal sheep Purkinje fibres and rat papillary muscles, buprenorphine (10-6-10-5 M) significantly reduced the action potential height and maximum rate of depolarisation of phase zero (MRD) and prolonged the duration of the action potential. Superfusion of sheep Purkinje fibres and rat papillary muscles with a hypoxic, hyperkalaemic and acidotic PSS resulted in marked reductions in resting membrane potential, upstroke and duration of the action potential. In the presence of the modified compared with normal PSS, buprenorphine reduced the action potential height and MRD of both sleep Purkinje fibres and rat papillary muscles to a greater extent, although its ability to prolong the action potential duration was attenuated. The antiarrhythmic effects of buprenorphine observed in vivo may be explained by its direct cardiac electrophysiological effects. Buprenorphine might be useful in relieving pain and in reducing the severity of arrhythmias in the early stages of acute myocardial infarction.

AB - The effects of buprenorphine, given intravenously, on the incidence and severity of early acute coronary artery occlusion-induced arrhythmias were examined in anaesthetised rats. The electrophysiological effects of buprenorphine were also examined in sheep Purkinje fibres and rat papillary muscles, superfused in vitro with either a normal or a hypoxic, hyperkalaemic and acidotic physiological salt solution (PSS). In anaesthetised rats subjected to acute coronary artery occlusion, pretreatment with buprenorphine (1 mg kg-1 i.v.) markedly reduced the incidence of ventricular extra-systoles during the initial 30 min post-occlusion period. The incidence of ventricular fibrillation (VF) was also significantly reduced from 56% to 10%. At the antiarrhythmic dose (1 mg kg-1), buprenorphine also attenuated the sudden fall in systemic arterial blood pressure induced by acute coronary artery ligation. In normal sheep Purkinje fibres and rat papillary muscles, buprenorphine (10-6-10-5 M) significantly reduced the action potential height and maximum rate of depolarisation of phase zero (MRD) and prolonged the duration of the action potential. Superfusion of sheep Purkinje fibres and rat papillary muscles with a hypoxic, hyperkalaemic and acidotic PSS resulted in marked reductions in resting membrane potential, upstroke and duration of the action potential. In the presence of the modified compared with normal PSS, buprenorphine reduced the action potential height and MRD of both sleep Purkinje fibres and rat papillary muscles to a greater extent, although its ability to prolong the action potential duration was attenuated. The antiarrhythmic effects of buprenorphine observed in vivo may be explained by its direct cardiac electrophysiological effects. Buprenorphine might be useful in relieving pain and in reducing the severity of arrhythmias in the early stages of acute myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=0024312289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024312289&partnerID=8YFLogxK

M3 - Article

C2 - 2758241

AN - SCOPUS:0024312289

VL - 97

SP - 801

EP - 808

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -